Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.

<h4>Background</h4>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). The studies are quite heterogenous regarding study size and populatio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaofeng Chen, Yiqian Liu, Oluf Dimitri Røe, Yingying Qian, Renhua Guo, Lingjun Zhu, Yongmei Yin, Yongqian Shu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0059314
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

Excellent response to gefitinib in a patient with erlotinib refractory, exon 21, L858r epidermal growth factor receptor-mutated lung adenocarcinoma
by: Ajay Gupta
Published: (2018-01-01)

Democratic and ethical problem of lung cancer screening: exclusion of true high-risk populations. Can it be fixed? Yes
by: Oluf Dimitri Røe
Published: (2020-09-01)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
by: Iwao Shimomura, et al.
Published: (2013-01-01)

Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study
by: Phyu Sin Aye, et al.
Published: (2025-03-01)

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.
by: Mi Seong Kim, et al.
Published: (2025-01-01)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
by: Vishwanath Sathyanarayanan, et al.
Published: (2014-01-01)

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER
by: S. A. Protsenko, et al.
Published: (2017-01-01)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer
by: Lei Tianyao, et al.
Published: (2022-04-01)

Correction: AlRasheed et al. Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats. <i>Pharmaceuticals</i> 2022, <i>15</i>, 1400
by: Hajer AlRasheed, et al.
Published: (2024-12-01)

Astragaloside IV sensitizes non–small cell lung cancer cells to gefitinib potentially via regulation of SIRT6
by: Peng-Chen Dai, et al.
Published: (2017-04-01)

EPHA5 enhances stemness and decreases gefitinib sensitivity via Wnt signaling pathway in non-small lung cancer
by: Jie Li, et al.
Published: (2025-03-01)

Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway
by: Jiali Wang, et al.
Published: (2024-12-01)

Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer
by: Huake Sun, et al.
Published: (2017-07-01)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
by: Xiaohui Zeng, et al.
Published: (2020-11-01)

Vibrational Fingerprint of Erlotinib: FTIR, RS, and DFT Studies
by: Natalia Piergies, et al.
Published: (2019-01-01)

Erlotinib-Associated Acute Pneumonitis: Report of Two Cases
by: Bobbak Vahid, et al.
Published: (2007-01-01)

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset
by: Makoto Nishio, MD, PhD, et al.
Published: (2025-06-01)

Perforating Corneal Ulceration in a Patient with Lung Metastatic Adenocarcinoma Treated with Gefitinib: A Case Report
by: Enjie Ibrahim, et al.
Published: (2012-01-01)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

Prognostic significance of calcium-related genes in lung adenocarcinoma and the role of TNNC1 in macrophage polarization and erlotinib resistance
by: Jian Feng, et al.
Published: (2025-05-01)

Gefitinib: Combination Therapy and Complex Delivery Systems (Review)
by: L. L. Nikolaeva, et al.
Published: (2024-03-01)

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells
by: Xiaoting Jia, et al.
Published: (2024-12-01)

First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients
by: Robert A Louis, et al.
Published: (2012-01-01)

Rosmarinic acid potentiates gefitinib in lung adenocarcinoma by modulating interactions between cancer cells and cancer-associated fibroblasts
by: Duo Li, et al.
Published: (2025-07-01)

Editorial: Direct or indirect endocrine and metabolic consequences of malignancies
by: Chen Wu, et al.
Published: (2024-11-01)

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
by: Yujing Wang, et al.
Published: (2024-12-01)

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib
by: Jing Zhang, et al.
Published: (2025-01-01)

Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway
by: Jingyuan Zhang, et al.
Published: (2025-01-01)

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
by: Zu-Yao Yang, et al.
Published: (2013-01-01)

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
by: Shun Lu, et al.
Published: (2024-09-01)

RETRACTED: Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
by: Yibo Zhao, et al.
Published: (2018-06-01)

Bullous fixed drug eruption due to erlotinib: A rare case report
by: Kallolinee Samal, et al.
Published: (2025-07-01)

Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
by: Rui Li, et al.
Published: (2013-01-01)

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
by: Yanjing Guo, et al.
Published: (2025-07-01)

Correction: Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway
by: Jingyuan Zhang, et al.
Published: (2025-02-01)

Physicochemical characterization and biological evaluation of amorphous solid dispersions of an anticancerous drug: Erlotinib HCl
by: K. P. Safna Hussan, et al.
Published: (2025-07-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)